An Organoid-based Functional Precision Medicine Trial in Osteosarcoma

RECRUITING

I'm interested ...!!

The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.

Conditions:

🦠 Osteosarcoma

🗓️ Study Start (Actual) 12 February 2024

🗓️ Primary Completion (Estimated) 1 January 2026

✅ Study Completion (Estimated) 1 January 2027

👥 Enrollment (Estimated) 40

🔬 Study Type OBSERVATIONAL

📊 Phase N/A

Locations:

📍 Los Angeles, California, United States

📋 Eligibility Criteria

Description

Inclusion / exclusion criteria - Group1:
- Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes
Inclusion / exclusion criteria - Group 2:
- Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes

Ages Eligible for Study: N/A to N/A (CHILD, ADULT, OLDER_ADULT)

Sexes Eligible for Study: ALL

Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted 26 September 2023
First Submitted that Met QC Criteria 26 September 2023
First Posted 3 October 2023

Study Record Updates